Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein subunit vaccine against COVID-19. The vaccine had already received approval for restricted use in emergency situations among adults.
Biological E. Limited (BE) today received Emergency Use Authorisation (EUA) from the Drugs Controller General of India (DCGI) for the administration of its Corbevax vaccine in children aged 12 to 18 years. The approval for restricted use in an emergency situation by the Indian drug regulator was granted on the basis of interim results of the ongoing phase II/III clinical study. Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein subunit vaccine against COVID-19. The vaccine had already received approval for restricted use in emergency situations among adults on December 28, 2020. Highlighting the benefits of expanding the vaccine to children, Mahima Datla, Managing Director, Biological E. Limited, said,
